Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Open-Label, Multi-Center Study to Investigate the Safety, PK, and Efficacy of Ori-C101 in Advanced Hepatocellular Carcinoma (HCC) Patients (BEACON)

NCT05652920 is registered in ClinicalTrials.gov with OriCell Therapeutics Co., Ltd. as lead sponsor.

NCT NCT05652920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05652920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Open-Label, Multi-Center Study to Investigate the Safety, PK, and Efficacy of Ori-C101 in Advanced Hepatocellular Carcinoma (HCC) Patients (BEACON)
Lead sponsor
OriCell Therapeutics Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 15, 2022
Completion date
December 31, 2026
Enrollment
105 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma